初步评估益生菌对接受多种药物化疗的多中心淋巴瘤患犬胃肠道症状的影响:随机安慰剂对照研究。

IF 1.3 Q2 VETERINARY SCIENCES Veterinary Record Open Pub Date : 2021-03-29 eCollection Date: 2021-12-01 DOI:10.1002/vro2.2
Maria C Jugan, Raelene M Wouda, Mary Lynn Higginbotham
{"title":"初步评估益生菌对接受多种药物化疗的多中心淋巴瘤患犬胃肠道症状的影响:随机安慰剂对照研究。","authors":"Maria C Jugan, Raelene M Wouda, Mary Lynn Higginbotham","doi":"10.1002/vro2.2","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Gastrointestinal (GI) toxicity is a major dose-limiting factor in dogs undergoing chemotherapy. A proposed mechanism of GI toxicity includes chemotherapy-driven GI dysbiosis. This study was designed to determine the effects of probiotic administration on GI side-effects in dogs receiving multi-agent chemotherapy.</p><p><strong>Methods: </strong>Ten client-owned dogs with multicentric lymphoma were enrolled in a prospective, randomised, placebo-controlled single-blinded study. On the first day of the cyclophosphamide doxorubicin vincristine prednisone (CHOP)-based chemotherapy protocol, dogs were randomised to receive either daily oral probiotic at a dose of 200 × 10<sup>9</sup> cfu/10 kg (n = 5) or daily oral placebo (n = 5). Complete blood count, faecal score (FS), faecal microbiome analysis (qPCR) and adverse events scores were performed at baseline and on the day of each subsequent chemotherapy dose, as well as 3 days after doxorubicin (days 0, 7, 14, 21, 24 and 28).</p><p><strong>Results: </strong>Overall, 40% of dogs had an abnormal GI microbiome at baseline, specifically decreased faecal <i>C. hiranonis</i> and <i>Fusobacterium</i> abundances. Dogs receiving probiotics had increased faecal <i>Streptococcus</i> (p = 0.02) and <i>E. coli</i>. (p = 0.01). No dogs receiving probiotics experienced diarrhoea (FS ≥ 3.5) compared to four of five receiving placebo. (F 2.895; p = 0.13).</p><p><strong>Conclusion: </strong>GI microbiome dysbiosis was common in this group of dogs with multicentric lymphoma. Probiotics were well-tolerated, with no negative side effects. Further studies are needed to explore broader microbiome and metabolome changes, as well as clinical benefit.</p>","PeriodicalId":23565,"journal":{"name":"Veterinary Record Open","volume":null,"pages":null},"PeriodicalIF":1.3000,"publicationDate":"2021-03-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8109851/pdf/","citationCount":"0","resultStr":"{\"title\":\"Preliminary evaluation of probiotic effects on gastrointestinal signs in dogs with multicentric lymphoma undergoing multi-agent chemotherapy: A randomised, placebo-controlled study.\",\"authors\":\"Maria C Jugan, Raelene M Wouda, Mary Lynn Higginbotham\",\"doi\":\"10.1002/vro2.2\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background: </strong>Gastrointestinal (GI) toxicity is a major dose-limiting factor in dogs undergoing chemotherapy. A proposed mechanism of GI toxicity includes chemotherapy-driven GI dysbiosis. This study was designed to determine the effects of probiotic administration on GI side-effects in dogs receiving multi-agent chemotherapy.</p><p><strong>Methods: </strong>Ten client-owned dogs with multicentric lymphoma were enrolled in a prospective, randomised, placebo-controlled single-blinded study. On the first day of the cyclophosphamide doxorubicin vincristine prednisone (CHOP)-based chemotherapy protocol, dogs were randomised to receive either daily oral probiotic at a dose of 200 × 10<sup>9</sup> cfu/10 kg (n = 5) or daily oral placebo (n = 5). Complete blood count, faecal score (FS), faecal microbiome analysis (qPCR) and adverse events scores were performed at baseline and on the day of each subsequent chemotherapy dose, as well as 3 days after doxorubicin (days 0, 7, 14, 21, 24 and 28).</p><p><strong>Results: </strong>Overall, 40% of dogs had an abnormal GI microbiome at baseline, specifically decreased faecal <i>C. hiranonis</i> and <i>Fusobacterium</i> abundances. Dogs receiving probiotics had increased faecal <i>Streptococcus</i> (p = 0.02) and <i>E. coli</i>. (p = 0.01). No dogs receiving probiotics experienced diarrhoea (FS ≥ 3.5) compared to four of five receiving placebo. (F 2.895; p = 0.13).</p><p><strong>Conclusion: </strong>GI microbiome dysbiosis was common in this group of dogs with multicentric lymphoma. Probiotics were well-tolerated, with no negative side effects. Further studies are needed to explore broader microbiome and metabolome changes, as well as clinical benefit.</p>\",\"PeriodicalId\":23565,\"journal\":{\"name\":\"Veterinary Record Open\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":1.3000,\"publicationDate\":\"2021-03-29\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8109851/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Veterinary Record Open\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1002/vro2.2\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2021/12/1 0:00:00\",\"PubModel\":\"eCollection\",\"JCR\":\"Q2\",\"JCRName\":\"VETERINARY SCIENCES\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Veterinary Record Open","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1002/vro2.2","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2021/12/1 0:00:00","PubModel":"eCollection","JCR":"Q2","JCRName":"VETERINARY SCIENCES","Score":null,"Total":0}
引用次数: 0

摘要

背景:胃肠道 (GI) 毒性是限制犬化疗剂量的一个主要因素。消化道毒性的一个拟议机制包括化疗导致的消化道菌群失调。本研究旨在确定服用益生菌对接受多种药物化疗的犬消化道副作用的影响:十只患有多中心淋巴瘤的客户自养犬被纳入一项前瞻性、随机、安慰剂对照单盲研究。在以环磷酰胺-多柔比星-长春新碱-泼尼松(CHOP)为基础的化疗方案开始的第一天,狗被随机分配到每天口服益生菌(剂量为 200 × 109 cfu/10 kg,n = 5)或每天口服安慰剂(n = 5)。在基线期、随后每次化疗当天以及多柔比星治疗后 3 天(第 0、7、14、21、24 和 28 天)进行全血细胞计数、粪便评分 (FS)、粪便微生物组分析 (qPCR) 和不良事件评分:总的来说,40%的狗在基线时胃肠道微生物组异常,特别是粪便中的平滑肌酵母菌和镰刀菌丰度下降。接受益生菌治疗的狗粪便中链球菌(p = 0.02)和大肠杆菌(p = 0.01)增加。(p = 0.01).服用益生菌的狗没有出现腹泻(FS ≥ 3.5),而服用安慰剂的五只狗中有四只出现腹泻。(F 2.895; p = 0.13):结论:在这组患有多中心淋巴瘤的狗中,消化道微生物群失调很常见。益生菌的耐受性良好,没有不良副作用。还需要进一步的研究来探讨更广泛的微生物组和代谢组变化以及临床益处。
本文章由计算机程序翻译,如有差异,请以英文原文为准。

摘要图片

摘要图片

摘要图片

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
Preliminary evaluation of probiotic effects on gastrointestinal signs in dogs with multicentric lymphoma undergoing multi-agent chemotherapy: A randomised, placebo-controlled study.

Background: Gastrointestinal (GI) toxicity is a major dose-limiting factor in dogs undergoing chemotherapy. A proposed mechanism of GI toxicity includes chemotherapy-driven GI dysbiosis. This study was designed to determine the effects of probiotic administration on GI side-effects in dogs receiving multi-agent chemotherapy.

Methods: Ten client-owned dogs with multicentric lymphoma were enrolled in a prospective, randomised, placebo-controlled single-blinded study. On the first day of the cyclophosphamide doxorubicin vincristine prednisone (CHOP)-based chemotherapy protocol, dogs were randomised to receive either daily oral probiotic at a dose of 200 × 109 cfu/10 kg (n = 5) or daily oral placebo (n = 5). Complete blood count, faecal score (FS), faecal microbiome analysis (qPCR) and adverse events scores were performed at baseline and on the day of each subsequent chemotherapy dose, as well as 3 days after doxorubicin (days 0, 7, 14, 21, 24 and 28).

Results: Overall, 40% of dogs had an abnormal GI microbiome at baseline, specifically decreased faecal C. hiranonis and Fusobacterium abundances. Dogs receiving probiotics had increased faecal Streptococcus (p = 0.02) and E. coli. (p = 0.01). No dogs receiving probiotics experienced diarrhoea (FS ≥ 3.5) compared to four of five receiving placebo. (F 2.895; p = 0.13).

Conclusion: GI microbiome dysbiosis was common in this group of dogs with multicentric lymphoma. Probiotics were well-tolerated, with no negative side effects. Further studies are needed to explore broader microbiome and metabolome changes, as well as clinical benefit.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Veterinary Record Open
Veterinary Record Open VETERINARY SCIENCES-
CiteScore
3.00
自引率
0.00%
发文量
25
审稿时长
19 weeks
期刊介绍: Veterinary Record Open is a journal dedicated to publishing specialist veterinary research across a range of topic areas including those of a more niche and specialist nature to that considered in the weekly Vet Record. Research from all disciplines of veterinary interest will be considered. It is an Open Access journal of the British Veterinary Association.
期刊最新文献
Determinants of Thoroughbred yearling sales price in the UK. Surveyed veterinary students in Australia find ChatGPT practical and relevant while expressing no concern about artificial intelligence replacing veterinarians. A scoping review on the use of reflection and reflective portfolio learning in veterinary education. Identifying veterinary surgeons’ barriers to, and potential solutions for, improving antimicrobial stewardship among sheep farmers in Northern Ireland Genotypic and allelic frequencies of progressive rod-cone degeneration and other main variants associated with progressive retinal atrophy in Italian dogs.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1